Camzyos and Weight decreased - a phase IV clinical study of FDA data

Summary:

Weight decreased is reported as a side effect among people who take Camzyos (mavacamten), especially for people who are female, 60+ old, also take Tylenol, and have Hypertrophic cardiomyopathy.

The phase IV clinical study analyzes which people have Weight decreased when taking Camzyos. It is created by eHealthMe based on reports of 1,625 people who have side effects when taking Camzyos from the FDA, and is updated regularly.

What is Camzyos?

Camzyos has active ingredients of mavacamten. eHealthMe is studying from 1,625 Camzyos users. Check the latest studies of Camzyos.

What is Weight decreased?

Weight decreased is found to be associated with 3,393 drugs and 4,747 conditions by eHealthMe. Check the latest studies of Weight decreased.

On Jul, 17, 2026

1,625 people reported to have side effects when taking Camzyos.
Among them, 20 people (1.23%) have Weight decreased.

Among these 20 people:

What is the gender of people who have Weight decreased when taking Camzyos? *

female: 70 %
male: 30 %

What is the age of people who have Weight decreased when taking Camzyos? *

What are other drugs people take besides Camzyos? *

What are other side effects people have besides Weight decreased? *

Weight Increased: 5 people, 25.00%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 4 people, 20.00%
Diarrhea: 4 people, 20.00%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 3 people, 15.00%
Tooth Disorder (tooth disease): 3 people, 15.00%
Swelling: 3 people, 15.00%
Depression: 3 people, 15.00%
Itching: 2 people, 10.00%
Agitation (state of anxiety or nervous excitement): 2 people, 10.00%
Cardiac Failure Congestive: 2 people, 10.00%

What are the existing conditions these people have? *

Hypertrophic Cardiomyopathy (a condition in which the heart muscle becomes abnormally thick): 17 people, 85.00%
Itching: 2 people, 10.00%
Depression: 2 people, 10.00%
Cardiac Failure Congestive: 2 people, 10.00%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 10.00%
Cardiomyopathy (weakening of the heart muscle): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Camzyos and have Weight decreased?

- Check whether Weight decreased is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Camzyos:

Camzyos (1,625 reports)

Weight decreased treatments and more:

Weight decreased (364,522 reports)

Browse all side effects of Camzyos:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Weight decreased:

Weight decreased (3,393 drugs)

Browse all the conditions that are associated with Weight decreased:

Weight decreased (4,747 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on mavacamten (the active ingredients of Camzyos) and Camzyos (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.